Autism Speaks Requests New Applications for Basic & Clinical Research Grants, Now At The Pilot And Full Levels

Date: 
February 04, 2011

February 4, 2011

Autism Speaks is pleased to announce its latest funding opportunities for researchers: Full- and Pilot-Level Basic & Clinical Grants.

Autism Speaks' mission is to improve the future for all who struggle with autism spectrum disorders (ASD). In support of that mission we provide funding along the entire research continuum -- from discovery to development to dissemination -- for innovative projects that hold considerable promise for significantly improving the lives of persons with autism.

Autism Speaks announces the launch of a new Request for Applications (RFA) to support both Basic & Clinical research grant applications at both the Full- and Pilot-Levels to conduct innovative biomedical and behavioral research into the causes, diagnosis, treatment, prevention and cure of ASD.

Pilot-Level B&C awards support projects in basic or clinical science that employ innovative approaches to explore untested hypotheses, develop preliminary data necessary to expand research, and/or are from beginning investigators or established investigators new to the field of autism research. Pilot-level grantees are eligible to receive up to $60,000 per year for a period of up to 2 years.

Full-level B&C awards support well developed research projects that build on existing and/or pilot-level feasibility data to further investigate basic or clinical biomedical and behavioral research, and that come from established or beginning investigators with demonstrated potential for and a commitment to autism research. Full-level award recipients are eligible for support at the level of $150,000 per year for a period of up to 3 years.

Applications must address one or more of the following 2011 priority research areas to be considered for funding:

  • Discovery and characterization of risk factors for autism, especially environmental risk factors and mechanisms for gene-environment interactions.
  • Development of methods for very early detection of ASD risk
  • Understanding factors that influence quality of life for adults with autism, emphasizing effective supports, functional outcomes, medical co-morbidities, and mortality.
  • Identification of the molecular pathophysiology of ASD that can inform translational research for drug discovery or development of diagnostic methods
  • Development and evaluation of novel treatments that can address the core symptoms and associated medical conditions throughout the lifespan
  • Dissemination of empirically-validated screening, diagnostic and treatment approaches

Registration for Pilot- and Full-Level Basic and Clinical applications is now open. Letters of Intent are due on March 15, 2011. For more information, please find the RFA here.

Tags: